PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3- d]thiophenes

Journal of Medicinal Chemistry

Volumn 42, Issue 17, 1999, Pages 3199-3202

  Wrobel, Jay ^a,c   Sredy, Janet ^a,d   Moxham, Christopher ^a   Dietrich, Arlene ^a   Li, Zenan ^a   Sawicki, Diane R ^a,d   Seestaller, Laura ^a   Wu, Li ^b   Katz, Alan ^a   Sullivan, Donald ^a   Tio, Cesario ^a   Zhang, Zhong Yin ^b  

^a PFIZER INC   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c WYETH AYERST RESEARCH   (United States)

^d The Institute for Diabetes Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; FURAN DERIVATIVE; GLUCOSE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HYPERGLYCEMIA; INSULIN RESISTANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN;

ANIMALS; ENZYME INHIBITORS; FURANS; HUMANS; HYPOGLYCEMIC AGENTS; MICE; MICE, OBESE; MODELS, MOLECULAR; PROTEIN-TYROSINE-PHOSPHATASE; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 13044270997     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990260v     Document Type: Article

References (22)

1. Bennett, P. H. Primary Prevention of NIDDM: A Practical Reality. Diabet. Metab. Rev. 1997, 13, 583-605.
2. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Longterm Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1993, 329, 977-986.
3. Kumar, S.; Boulton, A. J. M.; Beck-Nielsen, H.; Berthezene, F.; Muggeo, M.; Persson, B.; Spinas, G. A.; Donoghue, S.; Lettis, S.; Stewart-Long, P.; Group, F. T. T. Troglitazone, an Insulin Action Enhancer, Improves Metabolic Control in NIDDM Patients. Diabetologia 1996, 30, 701-709.
4. Witcher, J. W. Implications of the DCCT. A Pharmaceutical Industry Viewpoint and Commentary. Diabetes Rev. 1994, 2, 272-276.
5. Kahn, C. R. Insulin Action, Diabetogenes, and the Cause of Type II Diabetes. Diabetes 1994, 43, 1066-1084.
6. Goldstein, B. J.; Ahmad, F.; Ding, W.; Li, P.-M.; Zhang, W.-R. Regulation of the Insulin Signaling Pathway by Cellular Protein-Tyrosine Phosphatases. Mol. Cell. Biochem. 1998, 182, 91-99.
7. Byon, J. C. H.; Kusari, A. B.; Kusari, J. Protein-Tyrosine Phosphatase-1B acts as a Negative Regulator of Insulin Signal Transduction. Mol. Cell. Biochem. 1998, 182, 101-108.
8. Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A. L.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, C.-C.; Ramachandran, C.; Gresser, M. J.; Tremblay, M. L.; Kennedy, B. P. Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein Tyrosine Phosphatase-1B Gene. Science 1999, 283, 1544-1548.
9. Evans, J. L.; Jallal, B. Protein Tyrosine Phosphatases: Their Role in Insulin Action and Potential as Drug Targets. Exp. Opin. Invest. Drugs 1999, 8, 139-160.
10. Nutaitis, C. F.; Charles, F.; Patragnoni, R.; Goodkin, G.; Neighbour, B.; Obaza-Nutaitis, J. Reduction of Heterocyclic Alcohols with Sodium Borohydride-Trifluoroacetic acid. Preparation of Bis-Heterocyclic Methanes. Org. Prep. Proced. Int. 1991, 23, 403-411.
11. Phillion, D. P.; Andrew, S. S. Synthesis and Reactivity of Diethyl Phosphonomethyltriflate. Tetrahedron Lett. 1986, 1477-1480.
12. Barford, D.; Keller, J. C.; Flint, A. J.; Tonks, N. K. Purification and Crystallization of the Catalytic Domain of Human Protein Tyrosine Phosphatase 1B Expressed in Escherichia coli. J. Mol. Biol. 1994, 239, 726-730.
13. Lanzetta, P. A.; Alvarez, L. J.; Reinach, P. S.; Candia, O. A. An Improved Assay for Nanomole Amounts of Inorganic Phosphate. Ann. Biochem. 1979, 100, 95-97.
14. Yu, T.-F. Pharmacokinetic and Clinical Studies of a New Uricosuric Agent-Benzbromarone. J. Rheumatol. 1976, 3, 305-312.
15. Ferber, H.; Vergin, H.; Hitzenberger, G. Pharmacokinetics and Biotransformation of Benzbromarone in Man. Eur. J. Clin. Pharm. 1981, 19, 431-435.
16. Jia, Z.; Barford, D.; Flint, A. J.; Tonks, N. J. Structural Basis for Phosphotyrosine Peptide Recognition by Protein Tyrosine Phosphatase 1B. Science 1995, 268, 1754-1762.
17. Barford, D. J.; Flint, A. J.; Tonks, N. K. Crystal Structure of Human Protein Tyrosine Phosphatase 1B. Science 1994, 263, 1397-1404.
18. A detailed report on the kinetics of this compound and other related PTPase inhibitors will be submitted for publication.
19. Barford, D. J.; Jia, A.; Tonks, N. K. Protein Tyrosine Phosphatases Take Off. Nature Struct. Biol. 1995, 2, 1043-1053.
20. Wrobel, J.; Li, Z.; Dietrich, A.; McCaleb, M.; Mihan, B.; Sredy, J.; Sullivan, D. Novel 5-(3-Aryl-2-propynyl)-5-(Arylsulfonyl)-thiazolidine-2,4-diones as Antihyperglycemic Agents. J. Med. Chem. 1998, 41, 1084-1091.
21. Sredy, J.; Sawicki, D. R.; Flam, B. R.; Sullivan, D. Insulin Resistance is Associated with Abnormal Dephosphorylation of a Synthetic Phosphopeptide Corresponding to the Major Autophosphorylation of the Sites of the Insulin Receptor. Metabolism 1995, 44, 1074-1081.
22. Sredy, J. Unpublished data.